Results 161 to 170 of about 101,286 (277)

Impact of Sequential Ramucirumab Plus Docetaxel After PD‐1 Inhibitors on Anti‐PD‐1 Antibody‐Bound T‐Cell Dynamics and Clinical Outcomes

Cancer Science, EarlyView.
Ramucirumab (RAM) plus docetaxel (DOC) after PD‐1 inhibitors showed clinical activity, with responders exhibiting maintained anti–PD‐1 (IgG4+)‐bound CD8+ T cells and decreased IgG4+ Tregs. A sequential strategy of administering RAM plus DOC during persistent anti–PD‐1 antibody binding may be beneficial in patients with advanced non‐small cell lung ...
Kinnosuke Matsumoto, Yujiro Naito, Takayuki Shiroyama, Motohiro Tamiya, Kazumi Nishino, Akihiro Tamiya, Kyoichi Okishio, Yuhei Kinehara, Tomoki Kuge, Masahide Mori, Shingo Satoh, Hidekazu Suzuki, Satoshi Tetsumoto, Toshie Niki, Yasuhiko Suga, Akio Osa, Toshiyuki Minami, Shohei Koyama, Yoshito Takeda, Nobuyuki Takakura, Atsushi Kumanogoh   +20 more
wiley   +1 more source

Systemic Surveillance Guidelines for Uveal Melanoma: A Systematic Review

Clinical &Experimental Ophthalmology, EarlyView.
ABSTRACT Background Uveal melanoma (UM) is the most common primary intraocular tumour. Despite effective local therapies, UM has a high risk of metastatic recurrence, most frequently to the liver. A significant proportion of patients treated definitively for primary UM eventually experience metastatic disease. Systemic surveillance to detect recurrence
Farzana Y. Zaman, Aisha Ghaus, Mark Shackleton, Damien Kee, Anthony M. Joshua, Roderick O'Day, Malaka Ameratunga   +6 more
wiley   +1 more source

IL-2/IL-2Rβγ signaling in pruriceptors drives neuroimmune mechanisms of nivolumab-induced persistent itch. [PDF]

J Neuroinflammation
Li L, Zhao H, Guo J, Li H, Li A, Ba X, Wu F, Li N, Liu X, Wang X, Luo Y, Jiang C.   +11 more
europepmc   +1 more source

Phase 1b/2 study of BMS-813160, a CCR2/5 dual antagonist, in combination with chemotherapy or nivolumab in patients with advanced pancreatic or colorectal cancer. [PDF]

J Immunother Cancer
Le DT, Folprecht G, Varghese AM, Gutierrez M, Noel M, Trikalinos NA, Chen E, Dayyani F, Davis SL, Ma WW, BasuMallick A, Garrido-Laguna I, Osawa M, O'Brien S, Novosiadly RD, Xu K, Greenawalt DM, Dutta S, Twyman Saint Victor C, Lenz HJ.   +19 more
europepmc   +1 more source

Comparison of real-world efficacy and safety of nivolumab plus ipilimumab or pembrolizumab combined with platinum-based chemotherapy as first-line treatment for advanced non-small cell lung cancer in a German population. [PDF]

Cancer Immunol Immunother
Weber M, Freiherr von Hammerstein-Equord A, Weinreich M, Andreas S, Rittmeyer A.   +4 more
europepmc   +1 more source

Real‐world management of adjuvant systemic melanoma therapy: Multi‐center survey of 51 DeCOG skin cancer centers

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Background Adjuvant immune checkpoint inhibitors (ICI) and targeted therapy (TT) have revolutionized treatment management for patients with melanoma. However, the current German S3 guideline does not differentiate between patients with and without adjuvant therapy in its recommendations for imaging intervals and follow‐up monitoring, leading to
Markus Reitmajer, Elisabeth Livingstone, Lucie Heinzerling, Kai‐Martin Thoms, Frank Meiss, Markus V. Heppt, Anja Gesierich, Konstantin Drexler, Friedegund Meier, Max Schlaak, Andrea Forschner, Lisa Zimmer   +11 more
wiley   +1 more source

The Impact of Concurrent Proton Pump Inhibitors on Nivolumab Response in Metastatic Non-Small Cell Lung Cancer: A Multicenter Real-Life Study. [PDF]

Medicina (Kaunas)
Hendem E, Koçak MZ, Çetinkaya AM, Dinç G, Çağlayan M, Uğraklı M, Çağlayan D, Araz M, Eryılmaz MK, Sakin A, Eren OÖ, Tatlı AM, Geredeli Ç, Artaç M.   +13 more
europepmc   +1 more source

Complete lymph node dissection versus selective lymph node extirpation in melanoma patients with nodal macrometastasis and adjuvant systemic therapy

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Background and Objectives Complete lymph node dissection (CLND) is the standard of care in patients with regional nodal melanoma macrometastasis. However, evidence on surgical procedures in the era of adjuvant systemic therapies is lacking. Patients and Methods This retrospective multi‐center study included stage IIIB–D melanoma patients with ...
Kristine E. Mayer, Jessica C. Hassel, Jannik Sambale, Michael Erdmann, Mihaela‐Anca Sindrilaru, Julia Oberschmied, Alexander Thiem, Dirk Tomsitz, Jana Knuever, Max Schlaak, Carola Berking, Christian Posch, Tilo Biedermann, Oana‐Diana Persa   +13 more
wiley   +1 more source

Optimizing Nivolumab Efficacy: The Role of Dosing Time in Advanced Non-Small Cell Lung Cancer. [PDF]

Med Sci Monit
Ersoy M.
europepmc   +1 more source

Neoadjuvant therapy in skin cancer: current evidence and future perspectives

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary The development of immune checkpoint inhibitors and targeted therapies has fundamentally changed the treatment of cutaneous malignancies, especially in squamous cell carcinoma, melanoma, and Merkel cell carcinoma. The latest neoadjuvant approaches have shown promising results in locally advanced stages.
Lea Daniello, Johannes Kleemann, Bastian Schilling   +2 more
wiley   +1 more source